CN112638906A - 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法 - Google Patents

一种阿片样物质受体(mor)激动剂的结晶形式及制备方法 Download PDF

Info

Publication number
CN112638906A
CN112638906A CN201980053702.7A CN201980053702A CN112638906A CN 112638906 A CN112638906 A CN 112638906A CN 201980053702 A CN201980053702 A CN 201980053702A CN 112638906 A CN112638906 A CN 112638906A
Authority
CN
China
Prior art keywords
solvent
crystalline form
formula
crystal form
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980053702.7A
Other languages
English (en)
Other versions
CN112638906B (zh
Inventor
邵启云
杜振兴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN112638906A publication Critical patent/CN112638906A/zh
Application granted granted Critical
Publication of CN112638906B publication Critical patent/CN112638906B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种阿片样物质受体(MOR)激动剂的结晶形式及制备方法。具体地，提供(1S,4S)‑4‑乙氧基‑N‑(2‑((R)‑9‑(吡啶‑2‑基)‑6‑氧杂螺[4.5]癸‑9‑基)乙基)‑1,2,3,4‑四氢萘‑1‑胺富马酸盐(式(I)所示化合物)的II晶型及其制备方法。式(I)化合物的II晶型具备良好的晶型稳定性，可更好地用于临床治疗。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201980053702.7A 2018-10-12 2019-10-11 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法 Active CN112638906B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018111866699 2018-10-12
CN201811186669 2018-10-12
PCT/CN2019/110560 WO2020073984A1 (zh) 2018-10-12 2019-10-11 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法

Publications (2)

Publication Number Publication Date
CN112638906A true CN112638906A (zh) 2021-04-09
CN112638906B CN112638906B (zh) 2022-05-27

Family

ID=70163625

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980053702.7A Active CN112638906B (zh) 2018-10-12 2019-10-11 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法

Country Status (3)

Country Link
CN (1) CN112638906B (zh)
TW (1) TWI745764B (zh)
WO (1) WO2020073984A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113624898A (zh) * 2021-08-23 2021-11-09 成都诺和晟泰生物科技有限公司 一种手性镇痛类多肽药物的纯化方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103702561A (zh) * 2011-03-23 2014-04-02 特维娜有限公司 阿片样物质受体配体以及使用和制备其的方法
WO2017063509A1 (zh) * 2015-10-15 2017-04-20 江苏恒瑞医药股份有限公司 氧杂螺环类衍生物、其制备方法及其在医药上的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110049980B (zh) * 2017-04-14 2020-10-20 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的盐、其富马酸盐i晶型及制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103702561A (zh) * 2011-03-23 2014-04-02 特维娜有限公司 阿片样物质受体配体以及使用和制备其的方法
WO2017063509A1 (zh) * 2015-10-15 2017-04-20 江苏恒瑞医药股份有限公司 氧杂螺环类衍生物、其制备方法及其在医药上的应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113624898A (zh) * 2021-08-23 2021-11-09 成都诺和晟泰生物科技有限公司 一种手性镇痛类多肽药物的纯化方法
CN113624898B (zh) * 2021-08-23 2023-08-25 成都诺和晟泰生物科技有限公司 一种手性镇痛类多肽药物的纯化方法

Also Published As

Publication number Publication date
CN112638906B (zh) 2022-05-27
WO2020073984A1 (zh) 2020-04-16
TWI745764B (zh) 2021-11-11
TW202014188A (zh) 2020-04-16

Similar Documents

Publication Publication Date Title
CN110049980B (zh) 一种阿片样物质受体(mor)激动剂的盐、其富马酸盐i晶型及制备方法
CN108727347B (zh) 一种阿片样物质受体(mor)激动剂的晶型及其制备方法
EP3248983B1 (en) Crystal form a of obeticholic acid and preparation method therefor
KR20230054397A (ko) 전구약물 특성을 갖는 신규한 실로신 유도체
KR102142797B1 (ko) 피리디닐아미노피리미딘 유도체의 메실레이트 염의 결정질 형태, 그의 제조 방법, 및 그의 용도
CN110831932A (zh) 晶体形式的n-[1-(5-氰基-吡啶-2-基甲基)-1h-吡唑-3-基]-2-[4-(1-三氟甲基-环丙基)-苯基]-乙酰胺
KR20200054169A (ko) Ror 감마의 억제제
CN109937200B (zh) 一种苯并呋喃类衍生物游离碱的晶型及制备方法
WO2016140501A1 (en) Pyridine n-oxide for enhancer of zeste homolog 2 inhibitors
CN112638906B (zh) 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法
WO2022156761A1 (en) Spirocyclic indenes
WO2018072742A1 (zh) 一种咪唑并异吲哚类衍生物的游离碱的结晶形式及其制备方法
TW201827436A (zh) 一種ｊａｋ激酶抑制劑的硫酸氫鹽的晶型及其製備方法
CN112638907B (zh) 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法
CN115605202A (zh) 具有血清素受体结合活性的芳香族杂环衍生物
WO2021233133A1 (zh) 用作ret激酶抑制剂的化合物及其应用
EP2751094B1 (en) Novel crystal form
RU2779119C2 (ru) Соль агониста опиоидного рецептора (mor), кристаллическая форма i его фумаратной соли и способ их получения
CN115724846A (zh) 异喹啉磺酰衍生物新晶型及其制备方法和用途
TW201904972A (zh) 一種咪唑并異吲哚類衍生物游離鹼的晶型及其製備方法
WO2019161781A1 (zh) 受体抑制剂、包含其的药物组合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant